Don Lehr
General Counsel chez PRECIGEN, INC.
Fortune : 780 283 $ au 31/03/2024
Profil
Donald P.
Lehr is currently the Chief Executive Officer & Secretary at Genten Therapeutics, Inc. He is also the Secretary & Chief Legal Officer at Precigen, Inc. since 2009.
Previously, he served as the President, Treasurer & Director at GenVec, Inc. Mr. Lehr holds a graduate degree from The Johns Hopkins University, an undergraduate degree from Swarthmore College, and a graduate degree from The University of Maryland Francis King Carey School of Law.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PRECIGEN INC
0,22% | 05/04/2024 | 538 126 ( 0,22% ) | 780 283 $ | 31/03/2024 |
Postes actifs de Don Lehr
| Sociétés | Poste | Début |
|---|---|---|
| PRECIGEN, INC. | General Counsel | 01/01/2009 |
Genten Therapeutics, Inc.
 Genten Therapeutics, Inc. BiotechnologyHealth Technology Genten Therapeutics, Inc. operates as a biotechnology firm. It delivers a monotherapy through an antigen-specific induction of immune tolerance for gluten to address unmet medical need. The company is headquartered in San Francisco, CA. | Chief Executive Officer | - |
Anciens postes connus de Don Lehr
| Sociétés | Poste | Fin |
|---|---|---|
| GENVEC INC | President | - |
Formation de Don Lehr
| The Johns Hopkins University | Graduate Degree |
| Swarthmore College | Undergraduate Degree |
| The University of Maryland Francis King Carey School of Law | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PRECIGEN, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
GenVec, Inc.
 GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD. | Health Technology |
Genten Therapeutics, Inc.
Genten Therapeutics, Inc. BiotechnologyHealth Technology Genten Therapeutics, Inc. operates as a biotechnology firm. It delivers a monotherapy through an antigen-specific induction of immune tolerance for gluten to address unmet medical need. The company is headquartered in San Francisco, CA. | Health Technology |
